

# Omega-3-Acid Ethyl Esters & Icosapent Ethyl for Management of Hypertriglyceridemia in Adults

## Adjudication Guideline

**Rule Category:**  
Pharmaceutical

**Ref: No:**  
2024-PH-42

**Version Control:**  
Version No.V2.0

**Effective Date:**  
30/09/2025

**Revision Date:**  
22/08/2026

**Approved by:**  
Daman

**Responsible:**  
Pharmaceutical  
Standards& Governance

**Related Adjudication  
Guidelines:**N/A

## Table of Contents

|     |                                      |   |
|-----|--------------------------------------|---|
| 1.  | Abstract .....                       | 3 |
| 1.1 | For Members.....                     | 3 |
| 1.2 | For Medical Professionals.....       | 3 |
| 2.  | Scope .....                          | 3 |
| 3.  | Adjudication Policy.....             | 5 |
| 3.1 | Eligibility / Coverage Criteria..... | 5 |
| 3.2 | Requirements for Coverage .....      | 6 |
| 3.3 | Non-Coverage.....                    | 6 |
| 3.4 | Payment and Coding Rules .....       | 7 |
| 4.  | Denial Codes.....                    | 7 |
| 5.  | Appendices .....                     | 7 |
| 5.1 | References .....                     | 7 |
| 5.2 | Revision History .....               | 8 |

# 1. Abstract

## 1.1 For Members

Omega-3-Acid Ethyl Esters and Icosapent Ethyl are prescribed to help lower elevated triglyceride levels in adults with hypertriglyceridemia as part of a comprehensive treatment plan that includes diet and exercise. This medication must be taken under medical supervision.

## 1.2 For Medical Professionals

Omega-3-Acid Ethyl Esters and Icosapent Ethyl are prescription medication indicated for the management of hypertriglyceridemia in adults and as add on to prevent the risk of secondary myocardial infarction.

To assess its effectiveness, lipid panel evaluations are necessary. Long-term use should only be considered if there is a significant reduction in triglyceride levels. They are derived from marine sources and primarily contain eicosapentaenoic acid (EPA), with or without docosahexaenoic acid (DHA)

# 2. Scope

This Adjudication Rule outlines the coverage and payment requirements by Daman for Omega3-Acid Ethyl Esters and Icosapent Ethyl. It outlines the medical criteria for initial approval, continued therapy, and outlines the step therapy protocol applicable for coverage.

Omega-3-Acid Ethyl Esters and Icosapent Ethyl are lipid-regulating agents indicated as adjuncts to dietary measures for the reduction of elevated triglyceride levels in adult patients with severe hypertriglyceridemia: Type IV, Type IIb, or Type III hypertriglyceridemia

## Dose of Omega-3-Acid Ethyl Esters & Icosapent Ethyl:

- **Omega-3-Acid Ethyl Esters:** The recommended initial dose is 1-2 gram. If the reduction in triglyceride levels is insufficient after 6 months, the dosage may be increased to 4 grams per day (i.e., 4 soft capsules daily).
- **Icosapent Ethyl:** The recommended daily dose is 4 grams, which can be administered as:
  - Four 0.5-gram capsules taken twice daily with food, or
  - Two 1-gram capsules taken twice daily with food

| Generic Name              | Dose strength |
|---------------------------|---------------|
| Icosapent Ethyl           | 1000 mg       |
| Omega-3 acid ethyl esters | 1000 mg       |

## Mechanism Of Action:

### Inhibiting Triglyceride synthesis:


- It interferes with the production of VLDL in the liver, VLDL are the main carrier of triglycerides in the blood.

### Decreased Fatty Acids esterification:

- EPA and DHA compete with other fatty acids for incorporation into triglycerides within the liver, leading to reduced triglyceride production.

### Triglyceride breakdown:

- It promotes triglyceride breakdown within the liver and other tissues by oxidation.



<https://lipidworld.biomedcentral.com/articles/10.1186/s12944-016-0286-4>

## 3. Adjudication Policy

### 3.1 Eligibility / Coverage Criteria

#### Initial Approval Criteria:

Dietary and lifestyle interventions—including reduced intake of refined carbohydrates and added sugars, increased physical activity, weight management, and limited alcohol consumption—are considered first-line therapy in the management of hypertriglyceridemia. Pharmacologic treatment should only be initiated when these measures have been implemented, and triglyceride levels remain significantly elevated

- The patient has a confirmed diagnosis of hypertriglyceridemia corresponding to one of the following:
  - Type IV: Triglycerides  $\geq 500$  mg/dL despite dietary modifications
  - Type IIb or Type III: Triglycerides  $\geq 400$  mg/dL and not adequately controlled with statin therapy
- The patient has documented failure or intolerance to at least one of the following lipid-lowering therapies:
  1. Statins (e.g., atorvastatin, rosuvastatin)
  2. Fibrates (e.g., fenofibrate, gemfibrozil)

| Type                                               | Lipoprotein Abnormality        | Typical Triglyceride Level | Cholesterol Profile (mg/dL)                        |
|----------------------------------------------------|--------------------------------|----------------------------|----------------------------------------------------|
| <b>Type IV</b> (Familial Hypertriglyceridemia)     | ↑ VLDL                         | 500–1000+                  | Total: 200–300, LDL: 100–130, HDL: <40             |
| <b>Type IIb</b> (Familial Combined Hyperlipidemia) | ↑ VLDL and LDL                 | >400, often >1000          | Total: 250–350+, LDL: 130–190+, HDL: <40           |
| <b>Type III</b> (Dysbetalipoproteinemia)           | ↑ IDL and chylomicron remnants | >400, often >1000          | Total: 300–600+, LDL: normal or mildly ↑, HDL: <40 |

**American Board of Family Medicine (ABFM).** The article titled "Hypertriglyceridemia" <https://www.jabfm.org/content/jabfp/19/3/310.full.pdf>

#### Continued Therapy:

- A follow-up lipid panel should be obtained approximately one year after initiating therapy for severe hypertriglyceridemia.
- Continuation of therapy requires evidence of clinical benefit, such as a reduction in triglyceride levels, improved lipid parameters, or decreased cardiovascular risk markers.

**Target Reduction:**

- Achieving a decrease of 20% in triglyceride levels from baseline in patients with severe hypertriglyceridemia
- Effectiveness of the treatment should be evaluated with reassessments conducted every year.

**Stop therapy criteria:**

- **Failure to Achieve Target Levels:** If triglyceride levels remain significantly elevated and there is less than a 20% reduction from baseline after one year of treatment with Omega-3-Acid Ethyl Esters or Icosapent ethyl—despite confirmed adherence to dietary, lifestyle, and pharmacologic interventions—discontinuation of therapy may be considered.
- **Adverse Effects:** If the patient experiences significant side effects or adverse reactions (such as gastrointestinal issues, allergic reactions, or unusual bleeding), the medication should be stopped.

## 3.2 Requirements for Coverage

Kindly code the ICD-10 and the CPT codes to the highest level of specificity

**Red flags:**

- These agents are not considered first-line therapy for hypertriglyceridemia management.
- Omega-3-Acid Ethyl Esters and Icosapent Ethyl are considered adjunct and preventive therapies for patients at high risk of myocardial infarction, considering as a supplementary treatment
- Non-prescription omega-3 supplements are not approved for the treatment of severe hypertriglyceridemia

## 3.3 Non-Coverage

- Not covered for visitor plan
- Age less than 18 years

### 3.4 Payment and Coding Rules

- Kindly apply DOH payment rules and regulations and relevant coding manuals for ICD, Drugs.

| Eligible clinician Specialties |
|--------------------------------|
| Cardiology                     |
| Internal Medicine              |
| Endocrinology                  |
| Family Medicine                |

## 4. Denial Codes

| Code     | Code Description                                                                                                        |
|----------|-------------------------------------------------------------------------------------------------------------------------|
| MNEC-004 | Service is not clinically indicated based on good clinical practice, without additional supporting diagnoses/activities |
| MNEC-005 | Service(s) is(are) done/approved previously, request is too frequent                                                    |
| MNEC-006 | Alternative service should have been utilized                                                                           |
| CODE-010 | Activity/diagnosis inconsistent with clinician specialty                                                                |
| CODE-014 | Activity/diagnosis is inconsistent with the patient's age/gender                                                        |

## 5. Appendices

### 5.1 References

- [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2004/21654lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21654lbl.pdf)
- [Hypertriglyceridemia Management According to the 2018 AHA/ACC Guideline - American College of Cardiology](#)
- [Hypertriglyceridaemia - Treatment algorithm | BMJ Best Practice](#)
- [Hypertriglyceridemia : LearnYourLipids](#)
- [ESC/EAS Guidelines for the management of dyslipidemias \(escardio.org\)](#)
- [Association Between Omega-3 Fatty Acid Intake and Dyslipidemia: A Continuous Dose-Response Meta-Analysis of Randomized Controlled Trials - PMC \(nih.gov\)](#)

## 5.2 Revision History

| Date       | Change(s)                       |
|------------|---------------------------------|
| 02.07.2025 | Release of V1.0                 |
| 22.08.2025 | Add Triglyceride level per type |

### Disclaimer

By accessing these Daman Adjudication Guidelines, you acknowledge that you have read and understood the terms of use set out in the disclaimer below:

The information contained in this Adjudication Guideline is intended to outline the procedures of adjudication of medical claims as applied by the National Health Insurance Company – Daman PJSC (hereinafter "Daman"). The Adjudication Guideline is not intended to be comprehensive, should not be used as treatment guidelines and should only be used for the purpose of reference or guidance for adjudication procedures and shall not be construed as conclusive. Daman in no way interferes with the treatment of patient and will not bear any responsibility for treatment decisions interpreted through Daman Adjudication Guideline. Treatment of patient is and remains at all times the sole responsibility of the treating Healthcare Provider. This Adjudication Guideline does not grant any rights or impose obligations on Daman. The Adjudication Guideline and all of the information it contains are provided "as is" without warranties of any kind, whether express or implied which are hereby expressly disclaimed.

Under no circumstances will Daman be liable to any person or business entity for any direct, indirect, special, incidental, consequential, or other damages arising out of any use of, access to, or inability to use or access to, or reliance on this Adjudication Guideline including but without limitation to, any loss of profits, business interruption, or loss of programs or information, even if Daman has been specifically advised of the possibility of such damages. Daman also disclaims all liability for any material contained in other websites linked to Daman website.

This Adjudication Guideline is subject to the laws, decrees, circulars and regulations of Abu Dhabi and UAE. Any information provided herein is general and is not intended to replace or supersede any laws or regulations related to the Adjudication Guideline as enforced in the UAE issued by any governmental entity or regulatory authority, or any other written document governing the relationship between Daman and its contracting parties.

This Adjudication Guideline is developed by Daman and is the property of Daman and may not be copied, reproduced, distributed or displayed by any third party without Daman's express written consent. This Adjudication Guideline incorporates the Current Procedural Terminology (CPT®), which is a registered trademark of the American Medical Association ("AMA") and the CPT codes and descriptions belong to the AMA. Daman reserves the right to modify, alter, amend or obsolete the Adjudication Guideline at any time by providing one-month prior notice.